Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.
Adult
Age Factors
Aged
Allografts
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Bortezomib
/ administration & dosage
Carmustine
/ administration & dosage
Cytarabine
/ administration & dosage
Disease-Free Survival
Female
Hematologic Neoplasms
/ mortality
Humans
Lymphoma, Large B-Cell, Diffuse
/ mortality
Male
Melphalan
/ administration & dosage
Middle Aged
Podophyllotoxin
/ administration & dosage
Rituximab
/ administration & dosage
Stem Cell Transplantation
Survival Rate
Bortezomib
Lymphoma
Myeloablative allogeneic transplantation
R-BEAM
Journal
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
ISSN: 1523-6536
Titre abrégé: Biol Blood Marrow Transplant
Pays: United States
ID NLM: 9600628
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
14
08
2018
accepted:
19
02
2019
pubmed:
4
3
2019
medline:
2
7
2020
entrez:
4
3
2019
Statut:
ppublish
Résumé
Although bortezomib and rituximab have synergistic activity in patients with lymphoma and both can attenuate graft-versus-host disease (GVHD), the drugs have not been used together in patients undergoing allogeneic stem cell transplantation (alloSCT). In this phase I/II trial, we assessed the safety and activity of bortezomib added to the rituximab (R) plus BEAM (carmustine, etoposide, cytarabine, melphalan) regimen in patients with relapsed lymphoma undergoing alloSCT. Primary GVHD prophylaxis consisted of tacrolimus and methotrexate. Bortezomib (1 to 1.3 mg/m
Identifiants
pubmed: 30826465
pii: S1083-8791(19)30147-8
doi: 10.1016/j.bbmt.2019.02.022
pmc: PMC6615973
mid: NIHMS1525966
pii:
doi:
Substances chimiques
Cytarabine
04079A1RDZ
Rituximab
4F4X42SYQ6
Bortezomib
69G8BD63PP
Podophyllotoxin
L36H50F353
Melphalan
Q41OR9510P
Carmustine
U68WG3173Y
Banques de données
ClinicalTrials.gov
['NCT01538472']
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1347-1354Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Informations de copyright
Copyright © 2019 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
Références
Biol Blood Marrow Transplant. 2013 Jan;19(1):82-6
pubmed: 22897965
Biol Blood Marrow Transplant. 2014 Apr;20(4):536-42
pubmed: 24434781
Blood. 2008 Jun 15;111(12):5446-56
pubmed: 18216293
Proc Natl Acad Sci U S A. 2004 May 25;101(21):8120-5
pubmed: 15148407
Cancer. 2010 Feb 15;116(4):852-62
pubmed: 20041482
Blood. 2008 Jun 15;111(12):5530-6
pubmed: 18411419
Haematologica. 2018 Mar;103(3):522-530
pubmed: 29326124
J Clin Oncol. 1998 Aug;16(8):2817-24
pubmed: 9704734
Blood. 2014 Oct 2;124(14):2306-12
pubmed: 25145344
N Engl J Med. 2017 Nov 30;377(22):2167-2179
pubmed: 29171820
Blood. 2004 Dec 1;104(12):3535-42
pubmed: 15304387
Blood. 2013 Aug 22;122(8):1510-7
pubmed: 23861248
Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56
pubmed: 16338616
Biol Blood Marrow Transplant. 2016 Aug;22(8):1440-1448
pubmed: 27118571
Leukemia. 2008 Jan;22(1):179-85
pubmed: 17898787
Am J Med. 1980 Aug;69(2):204-17
pubmed: 6996481
Biol Blood Marrow Transplant. 2015 Nov;21(11):1907-13
pubmed: 26055298
Cancer J. 2012 Sep-Oct;18(5):457-62
pubmed: 23006952
Bone Marrow Transplant. 1995 Jun;15(6):825-8
pubmed: 7581076
Blood. 2004 Jan 15;103(2):428-34
pubmed: 12969983
Ann Oncol. 1999 May;10(5):527-32
pubmed: 10416001
Br J Haematol. 2018 Feb;180(3):365-373
pubmed: 29193021
Blood. 2002 Dec 15;100(13):4310-6
pubmed: 12393626
J Clin Oncol. 2007 Feb 10;25(5):579-86
pubmed: 17242396
J Clin Oncol. 2012 Sep 10;30(26):3202-8
pubmed: 22869883
J Clin Oncol. 2009 Oct 20;27(30):5023-30
pubmed: 19770386
Hum Immunol. 2000 Feb;61(2):92-100
pubmed: 10717800
Br J Haematol. 2005 Oct;131(2):223-30
pubmed: 16197454
Blood. 2009 Dec 3;114(24):4919-27
pubmed: 19749094
Clin Cancer Res. 2018 May 15;24(10):2304-2311
pubmed: 29476021
N Engl J Med. 2010 Nov 25;363(22):2091-101
pubmed: 21105791
J Clin Oncol. 1996 Jan;14(1):296-303
pubmed: 8558211
Blood. 2011 Mar 10;117(10):2807-12
pubmed: 21239695
Epidemiology. 2000 Sep;11(5):550-60
pubmed: 10955408
Blood. 2006 Jul 15;108(2):756-62
pubmed: 16551963
Biol Blood Marrow Transplant. 2013 Apr;19(4):632-9
pubmed: 23340040
J Clin Oncol. 2017 Apr 10;35(11):1154-1161
pubmed: 28380315
Blood. 2012 Jun 21;119(25):6145-54
pubmed: 22563089
Biol Blood Marrow Transplant. 2005 Aug;11(8):593-9
pubmed: 16041309